Evidence map›Paper›PMID 25956535›Full record

ArticleProtein expression and purification2015

Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.

Asterios I Grigoroudis, Campbell McInnes, Padmavathy Nandha Premnath, George Kontopidis

Open access · greenAbstract read
In one paragraph

Article in Protein expression and purification, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Asterios I GrigoroudisInstitute for Research and Technology-Thessaly (I.RE.TE.TH.) Centre for Research & Technology Hellas (CE.R.TH.), 95 Dimitriados & Pavlou Mela Street, GR 38333, Volos, Greece; Laboratory of Biochemistry, Faculty of Veterinary Science, University of Thessaly, GR-43100 Karditsa, Greece.
Campbell McInnesDrug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, United States.
Padmavathy Nandha PremnathDrug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, United States.
George KontopidisInstitute for Research and Technology-Thessaly (I.RE.TE.TH.) Centre for Research & Technology Hellas (CE.R.TH.), 95 Dimitriados & Pavlou Mela Street, GR 38333, Volos, Greece; Laboratory of Biochemistry, Faculty of Veterinary Science, University of Thessaly, GR-43100 Karditsa, Greece. Electronic address: gkontopidis@vet.uth.gr.
Centre for Research and Technology Hellas · GRUniversity of South Carolina · US

Funding

Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through RR01CA131368 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI MCINNES, CAMPBELL · 2008 to 2012
$1.4M
NCI NIH HHS 5R01CA131368NCI NIH HHS R01 CA131368
6 · The paper itself

Abstract

Bacterial expression of human proteins continues to present a critical challenge in protein crystallography and drug design. While human cyclin A constructs have been extensively characterized in complex with cyclin dependent kinase 2 (CDK2), efforts to express the monomeric human cyclin A2 in Escherichia coli in a stable form, without the kinase subunit, have been laden with technical difficulties, including solubility, yield and purity. Here, optimized conditions are described with the aim of generating for first time, sufficient quantities of human recombinant cyclin A2 in a soluble and active form for crystallization and ligand characterization purposes. The studies involve implementation of a His-tagged heterologous expression system under conditions of auto-induction and mediated by molecular chaperone-expressing plasmids. A high yield of human cyclin A2 was obtained in natively folded and soluble form, through co-expression with groups of molecular chaperones from E. coli in various combinations. A one-step affinity chromatography method was utilized to purify the fusion protein products to homogeneity, and the biological activity confirmed through ligand-binding affinity to inhibitory peptides, representing alternatives for the key determinants of the CDK2 substrate recruitment site on the cyclin regulatory subunit. As a whole, obtaining the active cyclin A without the CDK partner (referred to as monomeric in this work) in a straightforward and facile manner will obviate protein--production issues with the CDK2/cyclin A complex and enable drug discovery efforts for non-ATP competitive CDK inhibition through the cyclin groove.

Indexed as

Cyclin A2Escherichia coliHumansMolecular ChaperonesProtein BindingRecombinant Fusion ProteinsSolubilityCyclin A2Molecular ChaperonesRecombinant Fusion ProteinsMolecular chaperonesProtein–ligand binding affinityRecombinant human cyclin A2Soluble expressionTryptophan fluorescence titration

Identifiers

PMID25956535
PMCPMC4456239
OpenAlexW236732570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.